Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
A phase 1/2 trial of ISM6331 in mesothelioma, run by InSilico Medicine Hong Kong Limited, now recruiting.
Overview
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06566079 by InSilico Medicine Hong Kong Limited, with 160 participants planned, started 2024-12-27 and due to reach its primary completion in 2027-08-31. Interventions recorded: ISM6331.
Setting
A Phase 1/2, Open-Label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
Phase
Phase 1/2
Sponsor
InSilico Medicine Hong Kong Limited
Registry
Enrolled
160
Similar pages
not linked directly; found by shared links- TrialTT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Shares Mesothelioma and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Shares Mesothelioma and the tag pipeline.
- TreatmentEB-MF-CAR-NK-01
Shares Mesothelioma and the tag pipeline.